Core Viewpoint - The company, Maide Medical, is facing a significant decline in revenue and market challenges, particularly in its core safety infusion equipment segment, leading to concerns about its financial health and future prospects [2][3][4]. Revenue Performance - In 2024, Maide Medical's revenue plummeted by 42.77% year-on-year, totaling 275 million yuan, with core products experiencing substantial declines: safety infusion equipment revenue fell by 39.59%, and blood purification equipment revenue dropped to zero [2]. - The overall market for injection and puncture consumables in China shrank by 2.57% to 32 billion yuan, exacerbated by external pressures such as the FDA's safety reviews and tariffs on Chinese syringes [2]. Product Performance - The only bright spot was a 67.12% increase in revenue from blood purification connection machines, reaching 104 million yuan, although the average price halved from 20.78 million yuan to 8.01 million yuan [3]. - The shift towards lower-tier products in response to market demands raises concerns about the loss of technical premium and profitability [3]. Customer Concentration and Risks - The concentration of revenue among the top five customers increased, with the largest customer, Sanxin Medical, accounting for 32.65% of revenue (89.74 million yuan) and related transactions comprising 12.41% [3]. - The long repayment cycle of 1-3 years for major clients highlights potential liquidity risks for the company [3]. New Business Ventures - To counteract the decline in traditional business, Maide Medical is venturing into contact lens manufacturing through its subsidiary, Maide Shun, although this new business is currently in a cash-burning phase [4]. - Management expenses rose to 95 million yuan, and R&D expenses increased by 21.81% to 40 million yuan, with long-term loans of 30 million yuan fully invested in this new area [4]. Financial Health Indicators - Financial indicators are raising red flags, with inventory valued at 139 million yuan, constituting 22.99% of current assets, and a significant increase in contract liabilities by 78.59% to 98.84 million yuan [4]. - The company reported a goodwill impairment of 10.42 million yuan and a doubling of construction in progress to 50.01 million yuan, indicating potential asset bubble concerns [4].

Main Business - The company's main products include safety infusion devices and blood purification equipment, with significant revenue declines in safety infusion single machines and blood purification single machines, down 39.59% and 100.00% respectively, while blood purification continuous machines saw substantial growth [2][5][6] - The first major customer accounted for a significant portion of annual sales, with the increase in transaction amount attributed to the growth in the blood purification product business and the overall industry [2][14] Supplier Information - The company sources all standard parts externally, with a mix of self-manufactured, custom procurement, and outsourced processing for non-standard components. The total procurement amount for 2024 was 23,959.42 million yuan, a decrease of 36.99% compared to the previous year [28][29] Inventory and Contract Liabilities - The company reported that the inventory of blood purification single machines remained unsold due to production cycle delays and customer facility issues, impacting revenue recognition [11][12] - The company maintains a production model based on order fulfillment, which has led to fluctuations in sales revenue for blood purification single machines [11][12] Accounts Receivable and Long-term Receivables - The company provided details on its top five customers, including transaction amounts and payment conditions, indicating a healthy receivables situation with good recovery rates [13][15] Goodwill Impairment - There were no indications of impairment for the company's assets, as the net realizable value of blood purification single machines exceeded their costs, negating the need for inventory write-downs [12][25] Construction in Progress - The company has invested in the development of its contact lens manufacturing subsidiary, with a focus on material research and production line construction, indicating a strategic expansion into the optical sector [3][24] Market Trends - The blood dialysis medical device market in China is projected to grow steadily, with a compound annual growth rate of 5.67% from 2019 to 2023, expected to reach 51.515 billion yuan by 2030 [6][14] - The company is also expanding into the contact lens market, which is anticipated to grow significantly, with the transparent and colored contact lens markets projected to reach 161 billion yuan and 183 billion yuan respectively by 2030 [18][20]

Group 1 - The core viewpoint of the news is that Maide Medical's stock has seen a significant decline, with a closing price of 15.46 yuan, up 3.76%, and a market-to-book ratio of 3.27, marking a new low in 240 days, with a total market value of 2.57 billion yuan [1] - As of March 31, 2025, the number of shareholders in Maide Medical has increased to 3,997, up by 163, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - Maide Medical specializes in the research, production, sales, and service of medical consumables and intelligent equipment, with main products including safety infusion and blood purification devices [1] Group 2 - The latest financial results for the first quarter of 2025 show that Maide Medical achieved operating revenue of 40.18 million yuan, a year-on-year decrease of 45.87%, and a net profit loss of approximately 10.80 million yuan, a year-on-year decline of 202.70%, with a gross profit margin of 32.89% [1] - The company has received recognition for its innovation and intellectual property, being awarded the status of a national intellectual property advantage enterprise and a provincial intellectual property demonstration enterprise in 2022 [1] - In comparison to industry averages, Maide Medical's price-to-earnings (PE) ratio (TTM) is -62.23, and its market-to-book ratio is 3.27, indicating a significant deviation from the industry average PE ratio of 60.89 and market-to-book ratio of 4.16 [2]

截至2025年一季报，共有5家机构持仓迈得医疗，其中基金3家、其他1家、社保1家，合计持股数 1528.35万股，持股市值1.79亿元。 6月3日，迈得医疗今日收盘14.61元，上涨1.67%，最新市净率3.09，创231天以来新低，总市值24.28亿 元。 来源：金融界 迈得医疗工业设备股份有限公司主营业务是医用耗材智能装备的研发、生产、销售和服务。公司的主要 产品包括安全输注类、血液净化类两大类设备。公司获得浙江省博士后工作站设站资格；参与浙江省生 产制造方式转型示范项目、浙江省"尖兵""领雁"研发攻关计划项目；被评为2022年国家知识产权优势企 业、2022年浙江省知识产权示范企业。 最新一期业绩显示，2025年一季报，公司实现营业收入4017.63万元，同比-45.87%；净利 润-10797370.24元，同比-202.70%，销售毛利率32.89%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)23迈得医疗-58.81-121.543.0924.28亿行业平均 60.0468.404.0660.15亿行业中值49.6747.733.0939.59亿1中船应急-1721.88894.172 ...

5月28日，迈得医疗今日收盘14.03元，上涨3.47%，最新市净率2.97，创156天以来新低，总市值23.32亿 元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)23迈得医疗-56.48-116.712.9723.32亿行业平均 60.6169.154.0960.44亿行业中值47.5448.103.0340.71亿1中船应急-1717.48891.892.9777.07亿2利和 兴-859.91653.675.5246.28亿3开勒股份-781.59-473.506.5249.86亿4卓兆点胶-615.22-116.094.1524.09亿5博 杰股份-576.62233.902.5552.05亿6花溪科技-537.261173.119.3718.33亿7至纯科技-462.82411.322.0297.06亿 8爱司凯-357.32-1038.006.5231.51亿9蓝英装备-276.43-331.928.1672.22亿10舜禹股 份-273.01156.831.4621.41亿11鸿铭股份-180.85-186.632.1518.23亿 来源：金融界 迈得医疗工业设备股份有限公司主营业 ...

Company Overview - Jiangxi Sanxin Medical Technology Co., Ltd. specializes in the research, manufacturing, sales, and service of medical devices, with key products including blood purification devices, drug delivery devices, and cardiothoracic surgical instruments [2] - As of the end of 2024, the company holds 203 authorized patents, 121 pending patents, and has published 26 papers, demonstrating a strong commitment to technological innovation and R&D [2] - The company has been recognized as a "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration of China [2] Financial Performance - In the first quarter of 2025, the company reported revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, reflecting a slight increase of 0.20% year-on-year [2] - The gross profit margin for the same period was 34.62% [2] Market Position - As of May 28, the company's stock closed at 8.19 yuan, up 4.20%, with a rolling price-to-earnings (PE) ratio of 18.81, marking a new low in 46 days [1] - The average PE ratio for the medical device industry is 48.81, with a median of 35.46, placing Sanxin Medical at the 44th position in the industry ranking [1][3] - The total market capitalization of the company is 4.278 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 18,367, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Group 1 - The chairman and general manager of Maide Medical, Wang Yuling, increased her shareholding by 296,400 shares at an average price of 12.67 yuan, totaling 3.756 million yuan, bringing her total holdings to 494,300 shares [1][2] - Maide Medical's main business includes the manufacturing of molds, industrial automation control systems, laboratory analysis instruments, plastic products, industrial robots, and specialized machinery with independent functions, as well as software development and information system integration services [1] - As of December 31, 2024, the revenue breakdown for Maide Medical shows that safety infusion line machines generated 116 million yuan (42.18%), blood purification line machines 104 million yuan (37.90%), safety infusion single machines 38.6 million yuan (14.04%), and other revenues 16.1 million yuan (5.87%) [1] Group 2 - The latest market capitalization of Maide Medical is 2.254 billion yuan [2]

Group 1 - The chairman and general manager of Maide Medical, Wang Yuling, increased her shareholding by 195,900 shares at an average price of 11.59 yuan, totaling 2.2712 million yuan, resulting in a new holding of 197,800 shares [1][2] - Maide Medical's main business includes the manufacturing of molds, industrial automation control systems, laboratory analysis instruments, plastic products, industrial robots, and specialized machinery with independent functions, as well as software development and information system integration services [1] - As of December 31, 2024, the revenue breakdown for Maide Medical shows that safety infusion line machines generated 116 million yuan (42.18%), blood purification line machines 104 million yuan (37.90%), safety infusion single machines 38.6019 million yuan (14.04%), and other revenues 16.1469 million yuan (5.87%) [1] Group 2 - The latest market capitalization of Maide Medical is 1.961 billion yuan [2]

面对下游医疗耗材行业需求波动，迈得医疗把握人口老龄化加剧与制造强国战略推进的时代机遇，坚定 看好医疗器械行业长期发展前景。公司以研发创新为破局关键，全年研发投入4041.19万元，同比增长 21.81%，研发投入占营业收入比重达14.70%。迈得医疗持续加码技术攻关与产品迭代，进一步巩固核 心竞争优势，在行业震荡中聚势突围。 战略深耕破局突围，多维驱动提质进阶 伴随我国医保体系日趋完善，医保覆盖范围持续拓展，分级诊疗等政策加速落地实施，加之新技术与创 新模式不断投入临床应用，多重利好因素共同驱动医疗器械行业迈向高质量发展新阶段。《中国医疗器 械蓝皮书（2024版）》数据显示，2023年全球医疗器械市场规模达5826亿美元，同比增长5.40%；中国 市场规模突破万亿元大关，达到10328亿元，在稳健增长中展现出强大韧性。政策扶持、市场扩容与生 产自动化的协同推进，正成为医用耗材智能装备行业发展的核心引擎，推动生产模式向智能化、自动化 加速转型。 作为国际领先的透析器耗材设备供应商，迈得医疗拥有国内领先的安全输注类与血液净化类智能装备技 术与优质产品线。公司持续聚焦主业发展，为广大客户提供高附加值产品。公司"Ma ...

4月30日，迈得医疗今日收盘11.23元，上涨2.74%，最新市净率2.38，创19天以来新低，总市值18.67亿 元。 截至2025年一季报，共有5家机构持仓迈得医疗，其中基金3家、其他1家、社保1家，合计持股数 1528.35万股，持股市值1.79亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入4017.63万元，同比-45.87%；净利 润-10797370.24元，同比-202.70%，销售毛利率32.89%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)27迈得医疗-45.21-93.422.3818.67亿行业平均 57.8067.394.0158.05亿行业中值46.8745.612.9537.27亿1中船应急-1633.91848.492.8273.32亿2利和 兴-773.92588.304.9741.65亿3开勒股份-559.38-338.884.6735.69亿4卓兆点胶-557.58-105.213.7621.83亿5博 杰股份-505.91205.212.2445.67亿6至纯科技-467.39415.392.0498.02亿7爱司凯-351.11-1019.9 ...